Results Among the 172 patients, there were 73 males and 99 females, with an average age of 32 (28, 38) years, an average body weight of 89.8 (82.0, 101.2) kg, and an average BMI of 31.6 (30.0, 33.9) kg/m2. After 3 months of treatment, the total weight loss was 8.8% (5.6%, 13.6%), and the BMI decreased to 28.8 (27.0, 30.7) kg/m2. Measurements of waist circumference, waist-to-height ratio, body fat, body fat percentage, fat mass index (FMI), appendicular skeletal muscle mass index (ASMI), total muscle mass, visceral fat area (VFA), systolic blood pressure, diastolic blood pressure, and metabolic indicators [fasting glucose, postprandial blood glucose at 2 hours, fasting insulin, postprandial insulin at 2 hours, homeostatic model assessment of insulin resistance (HOMA-IR), triglycerides, cholesterol, low-density lipoprotein cholesterol, uric acid, alanine aminotransferase, and aspartate aminotransferase] all showed significant reductions compared to pre-treatment levels (P<0.05). Before treatment, 114 patients were classified as the ASCVD low-risk group, while 58 patients were classified as the moderate-to-high-risk group. Compared with the moderate-high risk group, the low-risk group showed a decrease in fasting glucose, postprandial blood glucose at 2 hours, postprandial insulin at 2 hours, HOMA-IR, triglycerides, cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, and aspartate aminotransferase, while high-density lipoprotein cholesterol increased before treatment (P<0.05). Among the 58 patients with moderate-to-high ASCVD risk before treatment, 36 patients transitioned to low risk after 3 months of treatment (risk decreased subgroup), while 22 patients remained in the moderate-to-high-risk category (risk stable subgroup). After 3 months of treatment, the body weight, BMI, waist circumference, waist-to-height ratio, body fat, body fat percentage, FMI, VFA, fasting insulin, postprandial insulin at 2 hours, insulin resistance index, triglycerides, alanine aminotransferase, and aspartate aminotransferase all decreased compared to pre-treatment levels in both subgroups. The risk decreased subgroup also showed decreases in systolic blood pressure, diastolic blood pressure, fasting blood glucose, cholesterol, and low-density lipoprotein cholesterol (P<0.05). The reductions in BMI, body fat, body fat percentage, FMI, and VFA in the reduction subgroup were significantly greater than those in the risk stable subgroup (P<0.05). Multivariate Logistic regression analysis indicated that BMI (OR=1.257, 95%CI=1.034-1.528, P=0.022) was an independent risk factor influencing the reduction of risk factors in obese patients with moderate-to-high ASCVD risk. For every 1 unit decrease in BMI, the ASCVD risk decreased by 25.7%. After 3 months of treatment, the proportion of patients at moderate-to-high ASCVD risk decreased than before in the liraglutide group (n=51), metformin group (n=61), and untreated group (n=60) (P<0.05), with no significant differences in ASCVD risk levels or weight loss indicators among the three groups (P>0.05). In the group with 28.0 kg/m2≤BMI<32.5 kg/m2 and the group with BMI≥32.5 kg/m2, the proportion of patients at moderate-to-high ASCVD risk decreased after 3 months of treatment, with the 28.0 kg/m2≤BMI<32.5 kg/m2 group showing a greater reduction in the proportion of patients at moderate-to-high ASCVD risk compared to the BMI≥32.5 kg/m2 group (P<0.05). Both the female and male groups showed a decrease in the proportion of patients at moderate-to-high ASCVD risk after 3 months of treatment (P<0.05), with no significant differences in ASCVD risk levels between the two groups (P>0.05). Comparisons between the 18-30 years group and the ≥30 years group also showed no significant differences in ASCVD risk levels (P>0.05) .